Hassan Fred — SEC Form 4 filings
SEC reporting owner CIK 1110744. 14 Form 4 filings on record with FilingPulse; latest filed 2026-06-24.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-03-12 to 2026-06-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| PRECIGEN, INC. (PGEN) | Director | 5 | — | — | 15 |
| BridgeBio Pharma, Inc. (BBIO) | Director | 3 | — | — | 5 |
| Cocrystal Pharma, Inc. (COCP) | Director | 3 | — | — | 4 |
| EyePoint, Inc. (EYPT) | Director | 3 | — | — | 3 |
Form 4 filings — Hassan Fred
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 3,990 @ $0 · Grant/award (A): 5,277 (derivative) @ $0 | EDGAR |
| 2026-03-16 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 71,839 · Option exercise (M): 71,839 (derivative) @ $0 | EDGAR |
| 2026-03-12 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 17,948 @ $3.51 · Grant/award (A): 35,612 (derivative) @ $0 · Grant/award (A): 41,073 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Cocrystal Pharma, Inc. (COCP) | Grant/award (A): 16,410 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | EyePoint, Inc. (EYPT) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-10-30 | 4 | Cocrystal Pharma, Inc. (COCP) | Grant/award (A): 359,713 @ $1.39 · Grant/award (A): 719,426 (derivative) @ $1.39 | EDGAR |
| 2025-06-24 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 6,589 @ $0 · Grant/award (A): 8,425 (derivative) @ $0 | EDGAR |
| 2025-03-17 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 36,206 @ $1.74 · Option exercise (M): 87,412 · Grant/award (A): 71,839 (derivative) @ $0 · Option exercise (M): 87,412 (derivative) @ $0 · Grant/award (A): 83,517 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-10-11 | 4 | Cocrystal Pharma, Inc. (COCP) | Grant/award (A): 8,067 | EDGAR |
| 2024-09-05 | 4 | EyePoint Pharmaceuticals, Inc. (EYPT) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | BridgeBio Pharma, Inc. (BBIO) | Grant/award (A): 26,014 (derivative) @ $0 | EDGAR |
| 2024-03-18 | 4 | PRECIGEN, INC. (PGEN) | Grant/award (A): 44,055 @ $1.43 · Grant/award (A): 87,412 (derivative) @ $0 · Grant/award (A): 101,626 (derivative) @ $0 | EDGAR |
| 2024-03-12 | 4 | PRECIGEN, INC. (PGEN) | Option exercise (M): 106,837 · Option exercise (M): 106,837 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1110744 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →